Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism
COPENHAGEN, Denmark, June 06, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that ... Read More
Ascendis Pharma A/S Reports First Quarter 2018 Financial Results
- Continued execution and achievement of planned milestones across three wholly-owned clinical programs in rare endocrine dis... Read More